News | January 10, 2024
Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Sirius JV will be owned 51% by Sirius and 49% by Adani
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Development services for gene and cell therapies is planned to begin first in 2025
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
